AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05104762 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: plasmapheresis device
Description: Group 1: 54 patients of Guillian Barrie syndrome undergo plasma exchange (5 sessions)
Study NCT05104762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous immunoglobulin
Description: group 2: 27 patients undergo intravenous injection of immunoglobulin for 5 consecutive days of IVIG 0.4gm/kg/day.
Study NCT06151431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: α-adrenergic receptor agonist
Description: The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
Study NCT04705025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Complete interview
Study NCT04705025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05293015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP-Supported Multidisciplinary Diabetes Management
Description: NP establishes files to evaluate and manage patients before hospital and visits patients after hospitalization. Then set blood glucose control goals with endocrinology and orthopedic doctors together, initiates consultation with endocrinologists for patients with postoperative hyperglycemia, and is responsible for post-hospital follow-up.
Study NCT05589272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: cognitive training + active-tDCS tDCS twice a day (two 13 minute sessions per day, each 2mA / 25cm² = 0.08 current density; anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for five consecutive days.
Study NCT05589272 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: cognitive training + sham-tDCS tDCS twice a day (two 13 minute sessions per day, each 2mA / 25cm² = 0.08 current density; anode on left dorsolateral prefrontal cortex F3, cathode on right dorsolateral prefrontal cortex F4) for five consecutive days.
Study NCT05420792 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peplau Interpersonal Relations based IPSRT will be applied to the intervention group
Description: IPSRT based on peplau Interpersonal Relations theory will be applied to the intervention group. First of all, information about the study will be given. An informed consent form will be filled and a history will be taken from the patient. With the Life Events Chart, past attacks and life events, interpersonal relations will be compared. Interpersonal Circle will be made to better understand the individual and relationships. A Joint Study Plan, which summarizes the disease history, life events, and interpersonal circle, will be created and presented to the patient in summary form. The patient will be given psychoeducation about his illness, drugs and social rhythms. A Social Rhythm Metric (SRM) will be created and monitored throughout therapy to assess their daily routine. Early warning signs of impending attacks will be discussed, managing symptoms, situations that may disrupt social rhythm will be determined (travel, vacation, moving, changing job)
Study NCT05736835 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVXGA
Description: CVXGA is a live viral vector, consisting of a recombinant parainfluenza virus type 5 that carries the SARS-CoV-2 S-protein from WA.1 (not enrolling) or XBB1.5 strain.
Study NCT05736835 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CVXGA
Description: CVXGA is a live viral vector, consisting of a recombinant parainfluenza virus type 5 that carries the SARS-CoV-2 S-protein from WA.1 (not enrolling) or XBB1.5 strain.
Study NCT04705025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06529237 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Malaria rapid diagnostic test
Description: Routine malaria rapid diagnostic tests
Study NCT04809064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic Bankart repair procedure
Description: Bankart repair with remplissage consists of arthroscopic anterior inferior capsulolabral repair with arthroscopic infraspinatus tenodesis to the posterior humeral head.
Study NCT04809064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Bankart
Description: Open Bankart repair consists of anterior capsulorrhaphy with labral repair.
Study NCT04809064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Latarjet
Description: Latarjet consists of open transfer of the coracoid to the anterior glenoid bone deficiency.
Study NCT04809064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-Operative Rehabilitation
Description: Post-operative rehabilitation will be conducted following surgical procedure-specific rehabilitation guidelines and will be progressed based on individual needs.
Study NCT06230341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Services Research
Description: MSPs benefit from a learning system. The learning system combines an individualised support programme provided by a regional support structure for quality and safety in health care (QualiREL Santé) and the provision of a web platform. Based on the 4 dimensions of the Shortell model, the support programme includes initial training (6 months) and personalised methodological support (18 months) for each MSP. A web platform is provided to MSPs to enable them to implement the full approach of the Risk Management Support Programme. It provides support for reporting, analysis and management of PSIs.
Study NCT06381960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuzheng Quxie Recipe
Description: Treatment group: Fuzheng Quxie Recipe (Yifei Sanjie Recipe) ingredients: Sheng Huang Qi 15g, Jiao Bai Zhu 15g, Bai Fu Ling 15g, Bei Sha Shen 15g, Zhe Mai Dong 15g, Dang Shen 15g, Shu Yang Quan 15g, Xia Ku Cao 15g, Sheng Mu Li 15g, Shi Jian Chuan 15g, Shi Shang Bai 15g, and Hai Zao 15g. Combined with basic chemotherapy after lung cancer.
Study NCT06381960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fuzhengquye Fang Recipe simulant
Description: Control group: Fuzhengquye Fang Recipe simulant, which was prepared into control group placebo drug according to 5% of the drug content in the treatment group. Combined with basic chemotherapy after lung cancer.
Study NCT05293964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0270
Description: SIM0270 is an oral, selective estrogen receptor degrader (SERD)
Study NCT05293964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: palbociclib is a selective inhibitor of cyclin D-cyclin-dependent kinase (CDK) 4/6
Study NCT05293964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus is an inhibitor of mTOR (mammalian target of rapamycin)
Study NCT05530031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trabeculotomy ( angle glaucoma surgery )
Description: a scleral flap is raised at the selected site with UBM and a cutdown in shlemm's canal is performed, a metal trabeculotome is used to cannulate and tear through a section of the inner wall of SC and trabeculum into the AC. Closure of the scleral flap and conjunctiva with 10/0 nylon. Viscoelastic is used to dilate the schlemm's canal, form the anterior chamber and decrease the risk of hyphema.
Study NCT05454306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anser Clavicle Pin
Description: The Anser Clavicle Pin is an intramedullary device that has been studied in 20 patients in an EU-based prospective case series.28 A 100% union rate was found. The Constant-Murley score at 1-year was 96.7 (SD 5). The Disabilities of Arm, Shoulder and Hand score was 5.1 (SD 10). There were no infections, neuropathy of the supraclavicular nerve or hardware irritation requiring removal of hardware. Three device-related complications (15%) occurred including plastic deformation, protrusion and hardware failure. VAS satisfaction was 8.9 (SD 1) at the 1-year follow up.
Study NCT04815031 — intervention group
Intervention type: BIOLOGICAL
Intervention: BNT162b2
Description: Comirnaty is administered intramuscularly after dilution as a course of 2 doses (0.3 mL each). It is recommended to administer the second dose 3 weeks after the first dose. Individuals 16 years of age and older.
Study NCT06679426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conestat Alfa
Description: See arm/group descriptions
Study NCT06679426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conestat Alfa
Description: See arm/group descriptions
Study NCT06678607 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reinovax PCV24 formulation 1
Description: One dose of Reinovax PCV24 formulation 1（0.5mL）
Study NCT06678607 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reinovax PCV24 formulation 2
Description: One dose of Reinovax PCV24 formulation 1（0.5mL）
Study NCT06678607 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: One dose of PPSV23 (0.5 mL) contains 1、2、3、4、5、6B、7F、8、9N、9V、10A、11A、12F、14、15B、17F、18C、19A、19F、20、22F、23F and33F saccharides.
Study NCT06678607 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of 0.5 mL placebo is aluminum phosphate adjuvant (aluminum content 0.25mg/dose), sodium chloride, succinic acid, polysorbate 80, and water for injection except for antigen components in 24-valent pneumococcal polysaccharide conjugate vaccine
Study NCT06679218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity Coaching Programme
Description: The intervention will consist of individualized physical activity coaching sessions, which will take place twice a week for 8 weeks. These sessions will focus on encouraging progressive and personalized physical activity according to each participant's ability. The sessions will also include relaxation techniques, targeted ventilation and strategies to improve activity management.
Study NCT06679218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical care and leaflet education
Description: In addition to standard medical care, patients assigned to this group received a leaflet with information about the main post COVID-19 condition symptoms. This is a control group that was not controlled or monitored by a therapist.
Study NCT05604651 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT04968600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total knee arthroplasty
Description: Posterior-cruciate-ligament is retained in one arm and sacrificed in another arm during total knee arthroplasty
Study NCT05761964 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Harmony & Health
Description: Participants will attend group in-person sessions 2 times each week for 8 weeks. The session will be 45 minutes long. In each session, there will be an introduction, 30 minutes of gentle yoga-based poses and breathing exercises, and then 10 minutes of guided relaxation and scripture meditation. Participants will be asked to complete at-home stretching practices 2 times each week for the 8 week intervention period. Participants will also be asked to complete weekly logs to self-monitor their physical activity.
Study NCT05761964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harmony & Health
Description: Participants will attend group in-person sessions 2 times each week for 8 weeks. The session will be 45 minutes long. In each session, there will be an introduction, 30 minutes of gentle yoga-based poses and breathing exercises, and then 10 minutes of guided relaxation and scripture meditation. Participants will be asked to complete at-home stretching practices 2 times each week for the 8 week intervention period. Participants will also be asked to complete weekly logs to self-monitor their physical activity.
Study NCT05761964 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Education
Description: Participants will attend group in-person health education sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long and will include discussions of disease prevention and other health and wellbeing topics.
Study NCT05761964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Participants will attend group in-person health education sessions 2 times each week for 8 weeks. The sessions will be 45 minutes long and will include discussions of disease prevention and other health and wellbeing topics.
Study NCT06428188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA/CD19 CAR-T cells
Description: The intervention in this clinical trial involves a novel approach using BCMA/CD19 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~BCMA/CD19 Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, BCMA/CD19 CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial BCMA/CD19 CAR-T cell infusion without unacceptable side effects and sufficient CAR-T cell availability may receive 2 or 3 additional doses.
Study NCT06642948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor rehabilitation based on ai visual recognition
Description: Patients in the intervention group will engage in a home-based exercise program in addition to standard rehabilitation guidance. Initially, patients will be provided with exercise materials developed by the intervention team, one-on-one guidance via the AI rehabilitation platform, and a detailed explanation of the exercise intervention program (including its components, foundational knowledge, and benefits).The aerobic warm-up routine includes activities such as marching in place, full-body stretches, jumping jacks, side steps with arm circles, and squats with alternating punches. For the elderly, the warm-up routine is similar but also incorporates chest expansion exercises, abduction exercises, overhead reaches, lateral movements, hip extension exercises, calf raises, and additional full-body stretches.Functional training should be done 3 to 5 times per week at an intensity of RPE 3 to 4, with each session lasting 15 to 30 minutes.
Study NCT06101069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRF in conjunction with IVIM MRI without contrast
Description: MRF in conjunction with IVIM MRI scan, without contrast.
Study NCT05924893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Hydrochloride
Description: naltrexone film
Study NCT05924893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboxy methyl cellulose
Description: Carboxy methyl cellulose drops
Study NCT05404113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sustained natural apophyseal glide
Description: Mulligan's C1-C2 self-SNAG+ strengthening exercises for anterior and posterior neck muscles (extension, flexion, rotation, lateral flexion) Frequency: 2-3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 20 minutes/session Type: Mobilization with movement SNAG Conventional PT including strengthening exercises neck muscles 10 repetitions, 1 set Resisted neck flexion, extension, lateral flexion, rotation Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 minutes/session Type: Strengthening Exercise
Study NCT05404113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deep friction massage
Description: Cyriax deep friction massage+ strengthening exercises for anterior and posterior neck muscles (extension, flexion, rotation, lateral flexion) Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 20 minutes/session Type: Deep soft tissue massage Conventional PT including strengthening exercises neck muscles 10 repetitions, 1 set Resisted neck flexion, extension, lateral flexion, rotation Frequency: 2-3 times/week for 3 weeks Intensity: moderate-high intensity (depending on pain tolerance) Time: 10 minutes/session Type: Strengthening Exercise
Study NCT04478175 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: multidisciplinary assessment and intervention
Description: early multidisciplinary assessment and intervention in addition to usual patient care
Study NCT06569953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Participants randomized to the intervention arm received 266 mg of liposomal bupivacaine for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline).
Study NCT06569953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Participants randomized to the intervention arm received 0.5% 100 mg of bupivacaine hydrochloride for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline)
Study NCT04720287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine/ neostigmine.
Description: will receive bilateral ultrasound guided QLB
Study NCT04720287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine/ neostigmine.
Description: will receive ultrasound guided CB.
Study NCT04543084 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Logbook
Description: Participants will record practice in a logbook.
Study NCT05259852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Assistance and Cessation Resources Navigation Plus Economic Assistance
Description: The intervention arm involves an initial telephone call with a community health worker (CHW). The content of the call focuses on providing participants with referrals for available food assistance resources in the community and referrals for tobacco cessation services. There are two additional follow-up calls approximately 4 weeks apart, for a total of 3 CHW navigator calls over the 12-week study period. In addition, the intervention arm involves providing participants with economic assistance for food in the form of a reloadable debit card ($83 every 4 weeks for 12 weeks, for a maximum amount of $250).
Study NCT05259852 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food Assistance and Cessation Resources Navigation
Description: The comparison arm involves an initial telephone call with a community health worker (CHW). The content of the call focuses on providing participants with referrals for available food assistance resources in the community and referrals for tobacco cessation services. There are two additional follow-up calls approximately 4 weeks apart, for a total of 3 CHW navigator calls over the 12-week study period.
Study NCT06273631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diverse carbohydrate diet
Description: Carbohydrate provides 45\~55% of total dietary energy, protein 15\~20%, and fat 25 \~35%. Among them, 45\~50% of carbohydrate supply sources are refined grains, 45\~50% of carbohydrate supply sources are whole grains or beans.~The total energy is divided into 3 meals per day. The breakfast provides 25\~30% of total energy, lunch 30\~40%，and dinner 30\~35%.
Study NCT06273631 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: middle carbohydrate diet
Description: Carbohydrate provides 45\~55% of total dietary energy, protein 15\~20%, and fat 25 \~35%. Among them, 90\~95% of carbohydrate supply sources are refined grains.~The total energy is divided into 3 meals per day. The breakfast provides 25\~30% of total energy, lunch 30\~40%，and dinner 30\~35%.
Study NCT06296212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAD® 600 mg/4 mL powder and solvent for solution for injection
Description: TAD® 600 mg/4 mL powder and solvent for solution for injection, 1 vial powder (glutathione sodium salt 646 mg) + 1 solvent ampoule (4 mL water for injection) reconstituted solution in 50 mL of 0.9% sodium chloride solution) administered intravenously (with an infusion rate of 10 mL/min), 2 times a day (with a dosing interval of 8 hours ± 30 minutes) for 5 consecutive days (Day 1, Day 2, Day 3, Day 4 and Day 5). Doses will be administered at the same time of the day (every 24 hours ± 30 minutes).
Study NCT06296212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution 0.9% of sodium chloride
Description: Placebo (50 mL of 0.9% sodium chloride solution) administered intravenously (with an infusion rate of 10 mL/min), 2 times a day (with a dosing interval of 8 hours ± 30 minutes) for 5 consecutive days (Day 1, Day 2, Day 3, Day 4 and Day 5). Doses will be administered at the same time of the day (every 24 hours ± 30 minutes).
Study NCT06261268 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strip graft with Mucograft
Description: An apically repositioned flap is made in the vestibular region. The flap is then elevated with a split-thickness preparation, and the mucogingival junction will be repositioned apically and fixed with periosteal-anchored sutures. Then, a free epithelialized gingival strip graft will be harvested from the molar area of the palate. The Strip graft is sutured to the apical end of the recipient bed. The remaining uncovered part of the periosteal bed will be covered with a xenogeneic collagen matrix (Mucograft®. Geistlich Pharma AG, Wolhusen, Switzerland) fixed with simple interrupted and crossed sutures. The edges of the palatal wound (donor area) will be approximated with crossed sutures.